IP Library › Granted Patent US 12,492,255
Granted Patent B2
US 12,492,255 · App. 19/217,020 · Granted Dec 9, 2025

Anti-TREM2 antibodies and methods of use

Inventors: Catherine Hoofd (Gosselies, BE); Thibaut Janss (Gosselies, BE); Romain Pirson (Gosselies, BE); Virginie Rabolli (Gosselies, BE); Yvonne McGrath (Gosselies, BE); Reece Marillier (Gosselies, BE); Quentin Dubray (Gosselies, BE); Clotilde Hoyos (Gosselies, BE); Julie Chesné (Gosselies, BE); Chiara Martinoli (Milan, IT); Stefan Loverix (Ternat, BE); Laura Saerens (Gosselies, BE)
Assignee: iTeos Belgium SA
C07K16/2803A61P35/00A61P37/04A61K2039/505C07K2317/52C07K2317/565C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,492,255
App. No.
19/217,020
Granted
Dec 9, 2025
Kind
B2
Abstract

Provided herein are anti-TREM2 antibodies. Polynucleotides, vectors, host cells, and methods of production are also provided herein. Methods of treating a disease or disorder, such as cancer with an anti-TREM2 antibody are further provided.

Claims (25)

1 . An antibody that specifically binds to TREM2, comprising a VH comprising CDRH1, CDRH2, and CDRH3, and a VL comprising CDRL1, CDRL2, and CDRL3, wherein the CDRH1, CDRH2, and CDRH3 comprise the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 109; and the CDRL1, CDRL2, and CDRL3 comprise the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 121; and wherein the amino acid sequences of the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 of the antibody are determined according to Kabat, Chothia, MacCallum, or IMGT numbering.

2 . The antibody of claim 1 , wherein the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 each comprise the CDRH1 sequence set forth in SEQ ID NO: 29, the CDRH2 sequence set forth in SEQ ID NO: 40, the CDRH3 sequence set forth in SEQ ID NO: 53, the CDRL1 sequence set forth in SEQ ID NO: 65, the CDRL2 sequence set forth in SEQ ID NO: 70, and the CDRL3 sequence set forth in SEQ ID NO: 82.

3 . The antibody of claim 1 , wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 109.

4 . The antibody of claim 1 , wherein the VL comprises the amino acid sequence set forth in SEQ ID NO: 121.

5 . The antibody of claim 1 , wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 109 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 121.

6 . The antibody of claim 1 , further comprising heavy and/or light chain constant regions.

7 . The antibody of claim 6 , wherein the heavy chain constant region comprises an amino acid sequence set forth in SEQ ID NO: 159 or SEQ ID NO: 160.

8 . The antibody of claim 6 , wherein the light chain constant region comprises an amino acid sequence set forth in SEQ ID NO: 157 or SEQ ID NO: 158.

9 . The antibody of claim 6 , wherein the heavy chain constant region comprises an amino acid sequence set forth in SEQ ID NO: 159 or SEQ ID NO: 160 and the light chain constant region comprises an amino acid sequence set forth in SEQ ID NO: 157 or SEQ ID NO: 158.

10 . The antibody of claim 5 , further comprising heavy and/or light chain constant regions.

11 . The antibody of claim 10 , wherein the heavy chain constant region comprises an amino acid sequence set forth in SEQ ID NO: 159 or SEQ ID NO: 160.

12 . The antibody of claim 10 , wherein the light chain constant region comprises an amino acid sequence set forth in SEQ ID NO: 157 or SEQ ID NO: 158.

13 . The antibody of claim 10 , wherein the heavy chain constant region comprises an amino acid sequence set forth in SEQ ID NO: 159 or SEQ ID NO: 160, and the light chain constant region comprises an amino acid sequence set forth in SEQ ID NO: 157 or SEQ ID NO: 158.

14 . The antibody of claim 6 , wherein the antibody comprises a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 168 or SEQ ID NO: 169, and a light chain comprising an amino acid sequence set forth in SEQ ID NO: 163.

15 . The antibody of claim 1 , wherein the antibody is conjugated to a cytotoxic agent, cytostatic agent, toxin, radionuclide, or detectable label.

16 . A polynucleotide or polynucleotides encoding a VH and/or a VL, or a heavy chain and/or a light chain of the antibody of claim 1 .

17 . An expression vector comprising the polynucleotide or polynucleotides of claim 16 .

18 . A host cell comprising the polynucleotide or polynucleotides of claim 16 .

19 . A method for producing an antibody that binds to human TREM2, comprising culturing the host cell of claim 18 under conditions which permit expression of the antibody.

20 . A composition comprising the antibody of claim 1 , and at least one pharmaceutically acceptable carrier.

21 . A method of reducing binding of low-density lipoprotein (LDL) to TREM2 in a subject, wherein the method comprises administering to the subject an effective amount of the antibody of claim 1 .

22 . A method of reducing efferocytosis in a subject, wherein the method comprises administering to the subject an effective amount of the antibody of claim 1 .

23 . A method of reprogramming macrophages in a subject, wherein the method comprises administering to the subject an effective amount of the antibody of claim 1 .

24 . A method of slowing, reducing, or inhibiting tumor growth in a subject, wherein the method comprises administering to the subject an effective amount of the antibody of claim 1 .

25 . A method of treating cancer in a subject, wherein the method comprises administering to the subject an effective amount of the antibody of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2025
From: HOOFD, CATHERINE; JANSS, THIBAUT; PIRSON, ROMAIN; RABOLLI, VIRGINIE; MCGRATH, YVONNE; MARILLIER, REECE; DUBRAY, QUENTIN; HOYOS, CLOTILDE; CHESNÉ, JULIE; MARTINOLI, CHIARA; LOVERIX, STEFAN; SAERENS, LAURA
To: ITEOS BELGIUM SA
Reel/Frame 071958/0104 →
Continuity (4)
Continuation 18821530 · Aug 30, 2024
Provisional Application 63640439 · Apr 30, 2024
Provisional Application 63580184 · Sep 1, 2023
Related Publication 20250282868A1 · Sep 11, 2025
References Cited (63)
US 9221902B2 · Smider · 2015 [cited by examiner]
US 10428143B2 · Krummel et al. · 2019 [cited by applicant]
US 11325973B2 · Krummel et al. · 2022 [cited by applicant]
US 20170334977A1 · Butovsky et al. · 2017 [cited by applicant]
US 20190330335A1 · Schwabe et al. · 2019 [cited by applicant]
US 20200277373A1 · Chen et al. · 2020 [cited by applicant]
US 20250101101A1 · Hoofd et al. · 2025 [cited by applicant]
WO WO2018015573A2 · 2018 [cited by applicant]
WO WO2018195506A1 · 2018 [cited by applicant]
WO WO2019028292A1 · 2019 [cited by applicant]
WO WO2019055841A1 · 2019 [cited by applicant]
WO WO2019118513A1 · 2019 [cited by applicant]
WO WO2020079580A1 · 2020 [cited by applicant]
WO WO2020112889A2 · 2020 [cited by applicant]
WO WO2020121195A1 · 2020 [cited by applicant]
WO WO2020123664A1 · 2020 [cited by applicant]
WO WO2020172450A1 · 2020 [cited by applicant]
WO WO2020172457A1 · 2020 [cited by applicant]
WO WO2020194317A1 · 2020 [cited by applicant]
WO WO2021113655A1 · 2021 [cited by applicant]
WO WO2021173565A1 · 2021 [cited by applicant]
WO WO2021174003A2 · 2021 [cited by applicant]
WO WO2021203030A2 · 2021 [cited by applicant]
WO WO2022040246A1 · 2022 [cited by applicant]
WO WO2022187092A1 · 2022 [cited by applicant]
WO WO2023039612A1 · 2023 [cited by applicant]
WO WO2023097327A1 · 2023 [cited by applicant]
WO WO2023172643A1 · 2023 [cited by applicant]
WO WO2024015560A1 · 2024 [cited by applicant]
WO WO2025046298A2 · 2025 [cited by applicant]
Kabat (The Journal of Biological Chemistry (1977) 252(19): 6609-6616) (Year: 1977). [cited by examiner]
Chothia (Journal of Molecular Biology (1987) 196: 901-917) (Year: 1987). [cited by examiner]
MacCallum (Journal of Molecular Biology (1996) 262: 732-745) (Year: 1996). [cited by examiner]
Lefranc (The Immunologist (1999) 7: 132-136) (Year: 1999). [cited by examiner]
Dondelinger (Frontiers in Immunology (2018) 9: Article 2278) (Year: 2018). [cited by examiner]
PCT International Search Report and Written Opinion from PCT/IB2024/000473, dated Mar. 13, 2025. [cited by applicant]
Deczkowska et al., “The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway,” Cell. 2020; 181(6):1207-1217. [cited by applicant]
Dujardin et al., “Fighting fire with fire: The immune system might be key in our fight against Alzheimer's disease,” Drug Discovery Today. 2022; 27(5):1261-1283. [cited by applicant]
Beckermann et al., “A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma,” In… [cited by applicant]
Binnewies et al., “Targeting TREM2 on tumor-associated macrophages enhances immunotherapy,” Cell Reports. 2021; 37(3):109844. [cited by applicant]
Cassetta and Pollard, “A timeline of tumour-associated macrophage biology,” Nature Reviews Cancer. 2023; 23:238-257. [cited by applicant]
Colonna, “The biology of TREM receptors,” Nature Reviews Immunology. 2023; 23(9):580-594. [cited by applicant]
Guerreiro et al., “TREM2 Variants in Alzheimer's Disease,” New England Journal of Medicine. 2013; 368(2):117-127. [cited by applicant]
Hou et al., “TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis,” Journal of Clinical Investigation. 2021; 131(4):e135197. [cited by applicant]
Jaitin et al, “Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner,” Cell. 2019; 178(3):686-698.e14. [cited by applicant]
Katzenelenbogen et al., “Coupled scRNA-Seq and Intracellular Protein Activity Reveal an Immunosuppressive Role of TREM2 in Cancer,” Cell. 2020; 182(4):872-885.e19. [cited by applicant]
Lopez-Yrigoyen et al, “Macrophage targeting in cancer,” Annals of New York Academy of Sciences. 2021; 1499(1):18-41. [cited by applicant]
Molgora et al, “TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy,” Cell. 2020; 182(4):886-900.e17. [cited by applicant]
Obradovic et al, “Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages,” Cell. 2021; 184(11):P2988-3005.E16. [cited by applicant]
Park et al, “TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer,” Nature Immunology. 2023; 24:792-801. [cited by applicant]
Patnaik et al “A phase 1a dose-escalation study of PY314, a TREM2 (Triggering Receptor Expressed on Macrophages 2) targeting monoclonal antibody,” Journal of Clinical Oncology. 2022; 40 (Suppl 16):2648. [cited by applicant]
Piollet et al, “TREM2 protects from atherosclerosis by limiting necrotic core formation,” Nature Cardiovascular Research. 2024; 3(3):269-282. [cited by applicant]
Schlepckow et al, “Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease,” The Lancet Neurology. 2023; 22(11):1048-1060. [cited by applicant]
Sun et al, “TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma,” Science Advances. 2023; 9(19):eade3559. [cited by applicant]
Wang et al, “Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model,” Journal of Experimental Medicine. 2020; 217(9):e20200785. [cited by applicant]
Wang et al, “Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development,” Immunity. 2023; 56(1):58-77.e11. [cited by applicant]
Xiong et al, “A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response,” Nature Communications. 2020; 11(1):5084. [cited by applicant]
Yofe et al, Spatial and temporal mapping of breast cancer lung metastases identify TREM2 macrophages as regulators of the metastatic boundary, Cancer Discovery. 2023; 13(12):2610-2631. [cited by applicant]
Yu et al, “TREM2 is associated with tumor immunity and implies poor prognosis in glioma,” Frontiers in Immunology. 2023; 13:1089266. [cited by applicant]
Zhang et al, “Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer,” Cancer Immunology, Immunotherapy. 2022; 71:2511-252… [cited by applicant]
Zhang et al, “Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment,” Cell Metabolism. 2022; 34(9):1359-1376.e7. [cited by applicant]
Zhang et al, “High TREM2 expression correlates with poor prognosis in gastric cancer,” Human Pathology. 2018; 72:91-99. [cited by applicant]
Zhang et al, “Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer,” Cancer Cell. 2021; 39(12):1578-1593.e8. [cited by applicant]